Nestlé Health Science and Epitomee Medical Ltd. enter into an agreement to develop and commercialize a novel weight loss and metabolic health product

epitomee logo

Lausanne, Switzerland August 11, 2020-- Nestlé Health Science and Epitomee Medical Ltd., a privately held Israel-based bio-medical company developing treatments for the overweight and obese population based on its gastric retention platform, have entered into a strategic partnership for the development and commercialization of an innovative polymer-based ingestible product aimed at promoting weight loss and improving health. The strategic partnership will cover the development and the commercialization of the product which has already demonstrated efficacy and safety in various pre-clinical and clinical studies with significant weight loss reduction and other beneficial health impacts.


Hans-Juergen Woerle, Chief Scientific & Medical Officer of Nestlé Health Science, said, "The research and development that Epitomee is doing is very promising. We look forward to working together to realize the commercialization of the product, an innovative approach to reducing weight and managing other associated metabolic health co-morbidities"


Dan Hashimshony PhD, CEO of Epitomee commented, “Nestlé Health Science is an ideal strategic partner for Epitomee. Its global reach, strategic intent to develop science-based nutritional health solutions and focus on fighting metabolic disorders will be instrumental to Epitomee’s worldwide commercialization success. We are excited about the opportunity that this deal brings to Epitomee and to the many millions of people around the world with obesity and other metabolic issues. This transformational deal is another recognition of the good science, the hard work, commitment and vision of our team."


Under the terms of the agreement, Epitomee grants Nestlé Health Science exclusive and global commercial rights to use the product in the weight loss market, and potentially to address other disorders including prediabetes and Type 2 Diabetes.


####


Nestlé Health Science (NHSc), a wholly owned subsidiary of Nestlé, is a globally recognized leader in the field of nutritional science. At NHSc we are committed to empowering healthier lives through nutrition for consumers, patients and their healthcare partners. We offer an extensive consumer health portfolio of industry-leading medical nutrition, consumer and VMS brands that are science-based solutions covering all facets of health from prevention, to maintenance, all the way through to treatment. NHSc is redefining the way we approach the management of health in several key areas such as pediatric health, allergy, acute care, oncology, metabolic health, healthy aging, gastrointestinal health, and inborn errors of metabolism. Headquartered in Switzerland, NHSc employs over 5,000 people around the world, who are committed to making a difference in people’s lives, for a healthier today and tomorrow.


Epitomee Medical Ltd. is a privately held company based in Israel that has developed a proprietary ingestible device platform technology to address metabolic disorders. The Epitomee gastric retention platform synergistically balances ingestible devices and the body’s native mechanism to tackle some of today’s most prevalent chronic diseases at their core. Epitomee’s drug-free, self-administered shape-shifting Capsule aims to prevent diabetes and address obesity comorbidities and establishing a healthier lifestyle. The company was co found by Shimon Eckhouse PhD.


Media contact: [email protected]